Pfizer ends inotuzumab ozogamicin Phase 3 non-Hodgkin lymphoma study

Pfizer has stopped the Phase 3 randomised, open-label study (B1931008) of inotuzumab ozogamicin in relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news